These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 27110499)

  • 1. The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice.
    Peng YL; Lee CT; Tain YL; Huang YB; Chuang HY; Wen YH; Huang SH; Tsai CY; Hsu CN
    PLoS One; 2019; 14(8):e0221504. PubMed ID: 31449565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orphan Drug Pricing: An Original Exponential Model Relating Price to the Number of Patients.
    Messori A
    Sci Pharm; 2016 Jan; 84(4):618-624. PubMed ID: 28656940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy.
    Messori A
    Clin Drug Investig; 2016 Aug; 36(8):599-603. PubMed ID: 27216427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
    Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
    PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Less Than One-third of Hospitals Provide Compliant Price Transparency Information for Total Joint Arthroplasty Procedures.
    Burkhart RJ; Hecht CJ; Acuña AJ; Kamath AF
    Clin Orthop Relat Res; 2022 Dec; 480(12):2316-2326. PubMed ID: 35901439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cure for the high cost of hepatitis C virus treatment.
    Etzion O; Ghany MG
    Ann Intern Med; 2015 May; 162(9):660-1. PubMed ID: 25820765
    [No Abstract]   [Full Text] [Related]  

  • 7. Using price-volume agreements to manage pharmaceutical leakage and off-label promotion.
    Zhang H; Zaric GS
    Eur J Health Econ; 2015 Sep; 16(7):747-61. PubMed ID: 25193525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter: estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of naïve patients with genotype 1 HCV infection in Italy.
    Messori A; Maratea D; Fadda V; Trippoli S
    Aliment Pharmacol Ther; 2014 Jul; 40(2):217-8. PubMed ID: 24946068
    [No Abstract]   [Full Text] [Related]  

  • 9. Discounts and rebates granted to public payers for medicines in European countries.
    Vogler S; Zimmermann N; Habl C; Piessnegger J; Bucsics A
    South Med Rev; 2012 Jul; 5(1):38-46. PubMed ID: 23093898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Criteria for Drug Pricing: Preliminary Experiences with Modeling the Price-Volume Relationship.
    Messori A
    Sci Pharm; 2016; 84(1):73-9. PubMed ID: 27110499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.